The New England journal of medicine
-
Randomized Controlled Trial
Trial of Intravenous Immune Globulin in Dermatomyositis.
Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been extensively evaluated. ⋯ In this 16-week trial involving adults with dermatomyositis, the percentage of patients with a response of at least minimal improvement based on a composite score of disease activity was significantly greater among those who received IVIG than among those who received placebo. IVIG was associated with adverse events, including thromboembolism. (Funded by Octapharma Pharmazeutika; ProDERM ClinicalTrials.gov number, NCT02728752.).